Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768538 | 0.75 | PKM (0.46) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL9768539 | 0.75 | CYP2A6 (0.45) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL1655642 | 0.71 | CYP2A6 (0.44) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL6983875 | 0.71 | ALDH1A1 (0.48) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL5360487 | 0.68 | CYP2A6 (0.60) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL16693129 | 0.68 | CYP2A6 (0.60) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL5722213 | 0.67 | NPC1 (0.48) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL29640474 | 0.67 | CYP2A6 (0.56) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL276823 | 0.67 | CYP2A6 (0.56) | CYP2A6MAPTPKMHDAC3HDAC4 | |
| SCHEMBL4381193 | 0.66 | CYP2A6 (0.54) | CYP2A6MAPTPKMHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713505-B2 | SUCH AS N-(2-((3-(AMINOOXOACETYL)-2-ETHYLBENZO(B)THIOPHEN-4-YL)OXY) ACETYL)GLYCINE; SECRETORY PHOSPHOLIPASE A2 (SPLA2) | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030236232-A1 | Novel spla2 inhibitors | ELI LILLY AND COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236232-A1 | Novel spla2 inhibitors | PLA2G2E, PLA2G4B, PLA2G12A | CYP2A6 1690/4885MAPT 4758/4885PKM 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.